Clinical trial
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With…
NCT00185393 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185393 |
|---|---|
| Title | Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy |
| Official title | Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Biological, Other |
| Interventions | Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128), no treatment |
| Enrollment | 414 |
| Start date | Aug 1, 2001 |
| Completion | Feb 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 1, 2008 |
| Countries | Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and 1 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: